COVID-19 drug Baricitinib: Eli Lilly signs voluntary licensing agreement with Natco Pharma

Natco has received approval from the Drug Controller General of India (DCGI) for Baricitinib earlier in May. Natco went ahead and launched the drug under brand name Barinat even as its compulsory licensing application is still pending before India. The patents of Baricitinib are owned by Lilly.

from Moneycontrol Business News https://ift.tt/3wc3SBq